Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017
May 30 2017 - 10:30AM
Accelerate Diagnostics, Inc. today announced that new data
from 11 healthcare institutions covering more than 1,200 samples
will be presented at the upcoming annual meeting of the American
Society for Microbiology – ASM Microbe in New Orleans, LA.
The data comes from external studies that evaluated the
potential clinical and workflow benefits of the Accelerate Pheno™
system and Accelerate PhenoTest™ BC kit compared to current
methods. The studies also include new early stage research on
potential whole blood applications.
ASM Microbe attendees can learn more about the potential impacts
of faster antibiotic susceptibility results direct from positive
blood cultures on patient treatment and antimicrobial stewardship
at four Industry and Science presentations, two live and unscripted
Q&A sessions with early clinical adopters, and ten poster
presentations.
All presentations will be held at the ASM Microbe Annual Meeting
June 2nd and 3rd in the Ernst N. Morial Convention Center in New
Orleans, LA.
For schedule information, speaker details, and a list of poster
presentations, visit http://acceleratediagnostics.com/asm2017.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro
diagnostics company dedicated to providing solutions for the global
challenge of antibiotic resistance and healthcare-associated
infections. The company’s Accelerate Pheno™ system and Accelerate
PhenoTest™ BC kit were recently cleared by the FDA for
antimicrobial susceptibility testing direct from positive blood
culture samples. The solution leverages proprietary molecular
identification methods and morphokinetic cellular analysis (MCA) to
provide minimum inhibitory concentrations for a range of applicable
antibiotics. The fully-automated system is designed to eliminate
the lengthy culture and sample preparation steps required prior to
antimicrobial susceptibility testing. To learn more, visit
axdx.com. The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” logos and marks are trademarks or registered
trademarks of Accelerate Diagnostics, Inc.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about the performance and
potential clinical and workflow benefits of our products, and
potential of future applications of our products. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Information about the risks
and uncertainties faced by Accelerate Diagnostics is
contained in the section captioned "Risk Factors" in the company's
most recent Annual Report on Form 10-K, filed with
the Securities and Exchange Commission on February
28, 2017, and in any other reports that we file with
the Securities and Exchange Commission from time to time.
The company's forward-looking statements could be affected by
general industry and market conditions. Except as required by
federal securities laws, the company undertakes no obligation to
update or revise these forward-looking statements to reflect new
events, uncertainties or other contingencies.
Media Contact:
Andrew Chasteen, Accelerate Diagnostics, achasteen@axdx.com, +1 520 365-3100
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024